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We demonstrate a critical role for Asn102 of the human
gonadotropin-releasing hormone (GnRH) receptor in
the binding of GnRH. Mutation of Asn102, located at the
top of the second transmembrane helix, to Ala resulted
in a 225-fold loss of potency for GnRH. Eight GnRH
analogs, all containing glycinamide C termini like
GnRH, showed similar losses of potency between 95- and
750-fold for the [Ala102]GnRHR, compared with wild-
type receptor. In contrast, four GnRH analogs that had
ethylamide in place of the C-terminal glycinamide resi-
due, showed much smaller decreases in potency be-
tween 2.4- and 11-fold. In comparisons of three agonist
pairs, differing only at the C terminus, glycinamide de-
rivatives showed an 11–20-fold greater loss of potency
for the mutant receptor than their respective ethylam-
ide derivatives. Thus Asn102 is a critical determinant of
potency specifically for ligands with C-terminal glyci-
namide, while ligands with C-terminal ethylamide are
less dependent on Asn102. These findings indicate a role
for Asn102 in the docking of the glycinamide C terminus
and are consistent with hydrogen bonding of the Asn102
side chain with the C-terminal amide moiety. Taken
with previous data, they suggest a region of the GnRH
receptor formed by the top of helices 2 and 7 as a binding
pocket for the C-terminal part of the ligand.
The hypothalamic decapeptide gonadotropin-releasing hor-
mone (GnRH)1 acts via receptors on gonadotrope cells of the
pituitary to control the release of luteinizing hormone and
follicle-stimulating hormone. GnRH receptors (GnRHRs)
cloned from mouse, rat, human, sheep, and cow are members of
the G-protein-coupled receptor superfamily (1–7). The GnRHR
is coupled via the Gq/G11 group of G-proteins to phospholipase
C (8). Agonist activation of the GnRHR results in an oscillatory
Ca21 signaling process (9) and gonadotropin exocytosis (10).
Because of the central role of GnRH in reproductive physiology,
a large number of peptide GnRH analogs has been synthesized,
and both agonist and antagonist analogs have found clinical
applications in a range of disorders of reproductive function
(11, 12). While nonpeptide analogs have been discovered for
several heptahelical peptide receptors including the opioid (13)
tachykinin (14), and angiotensin (15) receptors, nonpeptide
GnRH analogs remain to be described. Detailed knowledge of
the ligand binding site on the GnRHR is likely to facilitate
rational design of both novel peptide and nonpeptide GnRH
analogs.
Early studies showed that removal of the C-terminal glyci-
namide residue of GnRH led to a marked decrease in potency of
the peptide (11), suggesting an important interaction of the
glycinamide with the receptor. A modification that was found
to enhance the in vivo potency of GnRH was the replacement of




Tyr-Gly-Leu-Arg-Pro-CO-NH-CH2-CH3. The ethylamide modi-
fication was suggested to confer greater resistance to
enzymatic degradation (11) and has been incorporated in most
clinically used GnRH agonist analogs.
Site-directed mutagenesis provides a means for identifying
receptor residues involved in ligand binding. In a range of
G-protein-coupled receptors for peptide ligands, both the trans-
membrane helices and the extracellular domains have been
shown to contain residues that are important in binding (17).
When combined with systematic structural variation of the
ligand, receptor mutagenesis has the potential to elucidate
specific interactions between ligand and receptor. In a previous
study investigating the role of glycosylation in the GnRHR, we
found that Asn102, although present in a consensus N-glycosy-
lation sequence, is not in fact glycosylated (18). Surprisingly,
mutation of Asn102 to Gln resulted in an increased potency of
GnRH for the mutant receptor (18), which was due to increased
binding affinity (data not shown). These findings suggested the
possibility that Asn102, located at the top of transmembrane
helix 2, might be directly involved in the ligand binding site. In
the present study we have identified the side chain of Asn102 of
the GnRHR as an important determinant of agonist potency.
Furthermore, we show that the enhancement of potency con-
ferred by Asn102 is selective for peptides with a glycinamide
moiety at the C terminus, while the corresponding ethylamide
derivatives are less dependent on Asn102, indicating an impor-
tant role for this residue in the docking of the C-terminal
glycinamide of the ligand.
EXPERIMENTAL PROCEDURES
Reagents and Peptides—GnRH (pyro-Glu-His-Trp-Ser-Tyr-Gly-Leu-
Arg-Pro-Gly-NH2), [His
5,Trp7,Tyr8]GnRH (chicken II-GnRH), [Gln8]-
GnRH, [D-Trp6]GnRH, [D-Trp6,Pro9-NEt]GnRH were synthesized by
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conventional solid-phase methodology and purified by preparative C-18
reverse-phase high-pressure liquid chromatography. [Trp2]GnRH,
[D-Ser(But)6,Pro9-NEt]GnRH (buserelin) and [g-lactam6,7]GnRH were
gifts from J. Rivier, J. Sandow (Hoechst) and R. M. Freidinger (Merck),
respectively. GnRH free acid (GnRH-OH), [Pro9-NEt]GnRH, [D-Ala6]-
GnRH, and [D-Ala6,Pro9-NEt]GnRH were from Sigma. Peptide nomen-
clature follows that of Karten and Rivier (11).
Receptor Constructs and Site-directed Mutagenesis—The human Gn-
RHR cDNA (5) was shortened by removal of 1.3 kilobases of the 39-
untranslated region by digestion with SspI and cloned into the EcoRV
site of the phagemid pcDNA1/Amp (Invitrogen, San Diego, CA). Oligo-
nucleotide-directed mutagenesis was performed using the method of
Kunkel et al. (19). After passage through dut2,ung2,F9 strain Esche-
richia coli CJ236, uridine-containing antisense single-stranded DNA
template was prepared using VCS M13 helper phage (Stratagene). A
mutant oligonucleotide TGGGATGTGGGCCATTACAGTC was de-
signed to encode the Ala102 amino acid substitution. The oligonucleotide
was phosphorylated with T4 polynucleotide kinase (Promega Corp.) and
annealed with the template, and second strand synthesis was com-
pleted using T7 DNA polymerase (Bio-Rad) and T4 ligase (Bio-Rad).
Products of the reaction were used to transform competent E. coli strain
MV1109. Plasmid DNA from ampicillin-resistant colonies was se-
quenced, confirming the mutation, at the core facility of the Department
of Biochemistry, University of Bristol, U.K. Two independent
[Ala102]GnRHR clones, obtained from separate mutagenesis reactions,
were subsequently shown to exhibit indistinguishable phenotypes.
Transient Expression of GnRHRs—Plasmid DNA for transfection
was prepared using Qiagen columns (Qiagen) according to the manu-
facturer’s instructions. COS-1 cells were cultured in Dulbecco’s modi-
fied Eagle’s medium (Life Technologies, Inc.) containing 10% fetal calf
serum in a 10% CO2 atmosphere. For inositol phosphate production
assays, cells were seeded in poly-D-lysine-coated 12-well plates 1 day
before transfection, at 1.8 3 105 cells/well. For binding studies, 3 3 106
cells were seeded into 90-mm diameter dishes. Cells were transfected
by a modification of the DEAE-dextran method (20). Cells were washed
twice with phosphate-buffered saline, pH 7.4, and then incubated with
0.5 ml/well or 4 ml/dish of serum-free Dulbecco’s modified Eagle’s me-
dium containing 3.5–5 mg/ml plasmid DNA and 0.3 mg/ml DEAE-
dextran for 4 h at 37 °C. This was replaced with Dulbecco’s modified
Eagle’s medium containing 2% fetal calf serum and 150 mM chloroquine,
and incubation was continued for 1 h at 37 °C. The cells were washed
with phosphate-buffered saline, and finally cultured in Dulbecco’s mod-
ified Eagle’s medium with 10% fetal calf serum.
Inositol Phosphate Production—24 h after transfection, cells were
labeled overnight with 2 mCi/ml myo-[2-3H]inositol (Amersham Corp.)
in 0.25 ml/well Medium 199 (Life Technologies, Inc.) containing 5% fetal
calf serum, washed twice in HEPES-buffered saline (buffer A; Ref. 21),
and then stimulated with GnRH as indicated. Incubations were stopped
with perchloric acid/phytic acid solution, and following neutralization
with KOH, total inositol phosphates were chromatographed on Dowex
columns as described previously (21).
Data Reduction—Peptide concentrations required to stimulate half-
maximal IP production (EC50) were estimated by nonlinear regression
to the equation IP 5 IPmax/(1 1 EC50/A), where IP is the inositol
phosphate response to concentration A of agonist, and IPmax is the
maximal response, using Prism (Graphpad) software. Figures show
representative experiments in which data points are the mean 6 range
of duplicate determinations. Table I shows mean 6 S.E. of the indicated
number of independent experiments.
RESULTS
In COS-1 cells transiently expressing the [Ala102]GnRHR,
the EC50 for GnRH-stimulated inositol phosphate production
was increased by a mean of 225-fold, compared with the wild-
type receptor (Table I). In 15 independent experiments using
the 15 peptide agonists shown in Table I, the mean maximal
inositol phosphate response of the mutant receptor was 122%6
26% of the wild-type value (mean 6 S.D.). These results indi-
cated that the mutant receptor was expressed normally and
that the loss of potency of GnRH for the [Ala102]GnRHR can be
attributed predominantly or entirely to decreased binding af-
finity. Decreases in receptor number or coupling can cause a
large increase in EC50 without a decrease in maximal inositol
phosphate response only where there is a high degree of recep-
tor reserve (22). This was not the case in our experimental
system, since (a) GnRHR mutants, which have normal binding
affinity but are poorly expressed, e.g., glycosylation-defective
mutants, showed large decreases in maximal inositol phos-
phate responses, with only small increases in EC50 (18), and (b)
decreasing receptor number by chemical inactivation resulted
in a maximum increase in EC50 to 2.4 nM, a value similar to the
Kd of GnRH for binding (23). Therefore the increase in EC50 for
GnRH to 24.1 nM (Table I) without any accompanying decrease
in maximal inositol phosphate response, as exhibited by the
[Ala102]GnRHR, must be due predominantly or entirely to de-
creased affinity.
Binding experiments were performed with a number of dif-
ferent iodinated peptide radioligands to determine directly the
binding affinity of the [Ala102]GnRHR. While specific radioli-
gand binding by transiently expressed wild-type GnRHR in
COS-1 cells was easily measurable, binding by the mutant
receptor was undetectable, consistent with decreased affinity
for the radioligands.
To probe the possibility that Asn102 was a contact residue for
GnRH, dose-response curves for inositol phosphate production
were performed using a number of GnRH agonist analogs dif-
fering at various positions on the peptide, (Table I and Fig. 1).
The peptides [Trp2]GnRH, [His5,D-Tyr6]GnRH, [D-Ala6]GnRH,
TABLE I
Potencies of GnRH analogs for stimulation of inositol phosphate production in wild-type human GnRHR and [Ala102]GnRHR
EC50 values are the man 6 S.E. from n independent experiments. The potency loss values shown are the mean 6 S.E. of the ratio EC50









1. GnRH 0.114 6 0.030 24.1 6 7.03 225 6 41 4 G
2. [Pro9-NEt]GnRH 0.144 6 0.063 1.45 6 0.72 11.1 6 3.4 5 E
3. GnRH-OH 37.1 6 12.2 4610 6 1226 157 6 76 3
4. [D-Ala6]GnRH 0.087 6 0.022 10.8 6 5.25 110 6 25 4 G
5. [D-Ala6,Pro9-NEt]GnRH 0.028 6 0.014 0.220 6 0.075 9.59 6 2.21 3 E
6. [D-Trp6]GnRH 0.026 6 0.005 0.510 6 0.090 27.1 6 12.4 5 G
7. [D-Trp6,Pro9-NEt]GnRH 0.034 6 0.006 0.078 6 0.015 2.42 6 0.36 7 E
8. [Trp2]GnRH 0.036 6 0.003 3.43 6 0.99 94.4 6 23.5 3 G
9. [His5,D-Tyr6]GnRH 0.127 6 0.031 74.2 6 13.3 649 6 150 4 G
10. [His5,Trp7,Tyr8]GnRH 1.31 6 0.77 167 6 8.7 232 6 88 3 G
11. [D-lys6]GnRH 0.124 6 0.055 30.2 6 9.65 260 6 37 2 G
12. [g-lactam6,7]GnRH 0.040 6 0.010 4.30 6 0.06 116 6 29 2 G
13. [Gln8]GnRH 2.78 6 1.84 847 6 298 748 6 381 3 G
14. [Ala9]GnRH 4.60 453 98 1 G
15. [D-Ser(But)6,Pro9-NEt]GnRH 0.052 6 0.008 0.321 6 0.193 5.74 6 2.83 2 E


























[D-Lys6]GnRH, [g-lactam6,7]GnRH, [Gln8]GnRH, [Ala9]GnRH,
and [His5,Trp7,Tyr8]GnRH (chicken II GnRH) all demon-
strated potency losses between 94- and 750-fold in the mutant
receptor compared with wild-type receptor (peptides 4 and
8–14, Table I). All of these analogs contain glycinamide at their
C termini, as does the natural ligand GnRH, and their decrease
in potency for the [Ala102]GnRHR was similar to that of the
natural ligand. One peptide containing a C-terminal glyci-
namide, [D-Trp6]GnRH, showed only a mean 27-fold loss of
potency in the mutant receptor compared with wild-type recep-
tor (peptide 6, Table I). Analogs with amino acid substitutions
at positions 1, 3, and 4 were not studied, either because of
nonavailability of such peptides or on account of their very low
affinities for the wild-type receptor. Very low affinity analogs
were considered unsuitable for the purpose of delineating bind-
ing site contact residues because of the likelihood that they
might bind in a different configuration from GnRH and its high
affinity analogs.
In contrast, peptides in which the C-terminal glycinamide of
GnRH is substituted with ethylamide, [Pro9-NEt]GnRH,
[D-Ala6,Pro9-NEt]GnRH, [D-Trp6,Pro9-NEt]GnRH, and [D-Ser
(But)6,Pro9-NEt]GnRH (buserelin) showed only small increases
in EC50 between 2.5- and 11-fold (peptides 2, 5, 7, and 15; Table
I). Thus the ethylamide-substituted peptides displayed less
selectivity for the wild-type receptor than peptides with gly-
cinamide C termini. Fig. 2 shows a graphical representation of
these data (-fold potency loss plotted against log [EC50] for each
analog) and reveals the clear delineation of the glycinamide
versus ethylamide peptides in terms of potency reduction by the
mutation.
Direct comparisons of three peptide pairs differing only at
their C termini (peptides 1 and 2, 4 and 5, 6 and 7; Table I),
revealed that in each pair, the glycinamide derivative was more
dependent on Asn102 for potency than its corresponding ethyl-
amide derivative (Fig. 1). The C-terminal ethylamide substitu-
tion had little effect on the potency of these agonists for the
wild-type receptor. However, when interacting with the
[Ala102]GnRHR, the ethylamide-substituted peptides showed
markedly higher potency than their glycinamide-containing
derivatives. In these three peptide pairs, the C-terminal glyci-
namide moiety per se accounted for an 11–20-fold selectivity for
wild-type GnRHR compared with [Ala102]GnRHR (Table I and
Fig. 1).
GnRH-OH, which has a free carboxyl group at its C termi-
nus, was 325-fold less potent than GnRH and exhibited a
157-fold selectivity between mutant and wild-type receptors, a
value similar to that found for the glycinamide-containing an-
alogs (Table I).
DISCUSSION
Systematic variation of the structure of a ligand as well as
mutation of its receptor offers the possibility of identifying
specific ligand-receptor contact points. In principle, removal of
an interacting side chain of the receptor by mutating the resi-
due to Ala, should produce a decrease in affinity that is similar
in magnitude to, but nonadditive with, removal of the interact-
ing group from the ligand. The ratio EC50mut/EC50wt is a meas-
ure of the loss of potency for an analog due to the receptor
mutation. We demonstrate here that removal of the side chain
of Asn102 of the human GnRHR resulted in a 225-fold potency
loss of GnRH for stimulation of inositol phosphate production.
Thus for any particular GnRH analog, a potency loss equal to
that for GnRH would indicate that the analog in question
retains the same interaction with Asn102 as does GnRH. The
converse result, i.e., a potency loss significantly less than that
for GnRH, would suggest that the interaction of the peptide
with Asn102 is diminished or absent.
Eight GnRH analogs with substitutions at amino acids 2, 5,
6, 7, 8, or 9 exhibited potency losses of 94–750-fold for the
[Ala102]GnRHR relative to the wild-type receptor (Table I).
Since these potency losses are similar to the value of 225 for
GnRH, these results argue against an interaction of Asn102
with the side chains of residues at positions 2, 5, 6, 7, 8, and 9
in the peptide. Four of these peptides had glycine at position 6
as in GnRH, and four were “constrained” analogs with D-Ala6,
D-Lys6, D-Tyr6, or g-lactam6,7 substitutions, which enhance
FIG. 1. Dose-response curves for inositol phosphate produc-
tion stimulated by pairs of GnRH agonist analogs differing only
at their C termini. Peptide numbering as in Table I is shown in
parentheses. A, GnRH (peptide 1); B, [Pro9-NEt]GnRH (peptide 2); C,
[D-Ala6]GnRH (peptide 4); D, [D-Ala6,Pro9-NEt]GnRH (peptide 5); E,
[D-Trp6]GnRH (peptide 6); F, [D-Trp6,Pro9-NEt]GnRH (peptide 7). Open
circles, human wild-type GnRHR; filled circles, [Ala102]GnRHR.
FIG. 2. Selectivity of GnRH analogs for wild type GnRHR over
[Ala102]GnRHR. For each agonist, the potency loss for mutant versus
wild-type receptor (EC50mut/EC50wt) is plotted against EC50wt. Filled
circles, peptides with glycinamide C termini;Open circles, peptides with
ethylamide C termini.


























binding affinity and have been widely used in both agonist and
antagonist GnRH analogs (11). It has been proposed that these
substitutions stabilize the formation of a b-II type bend in the
peptide, resulting in a preferred conformation for binding (24,
25). The “constrained” analogs were included in the series
because we had previously found that these peptides showed a
different pattern of behavior from Gly6-containing peptides with
respect to their interaction with the mouse [Glu301]GnRHR (26).
The present data show, however, that they are similar to the
Gly6-containing peptides in that they display high selectivity
for the wild-type receptor over the [Ala102]GnRHR.
In contrast, four analogs with an ethylamide substitution for
glycinamide at the C terminus exhibited much smaller losses of
potency, between 2.4- and 11-fold, for the mutant receptor,
indicating that these peptides were all markedly less depend-
ent for high potency on the presence of Asn102. The role of the
ethylamide substitution per se was evaluated by comparing the
potencies of three pairs of peptides, each differing only at the C
terminus. Within each pair, the glycinamide derivative showed
an 11–20-fold greater potency loss for the [Ala102]GnRHR than
its corresponding ethylamide derivative.
[D-Trp6]GnRH was somewhat anomalous in that it exhibited
only a 27-fold loss of potency for the [Ala102]GnRHR compared
with wild-type GnRHR, despite the fact that it has a glyci-
namide C terminus (Fig. 1, Table I). This indicates that the
D-Trp6 substitution per se decreased the dependence on Asn102
for binding, presumably as a result of an interaction of the
D-Trp6 side chain with another site on the receptor. However,
its ethylamide derivative showed a loss of potency of only
2.4-fold, indicating that, similar to the other peptide pairs, the
glycinamide moiety was independently responsible for an 11-
fold selectivity of this peptide for the wild-type receptor over
the [Ala102]GnRHR.
These results indicate that Asn102 is critical in determining
high potency for peptides with glycinamide C termini, while
analogs with ethylamide C termini are less dependent on the
presence of Asn102. The most direct interpretation of these data
suggests that the Asn102 side chain is a contact point for gly-
cinamide-containing ligands and, more specifically, that Asn102
is hydrogen bonded with the C-terminal amide group of GnRH.
It should be noted that the ethylamide peptides do show some
dependence on Asn102 (although less than the glycinamide
peptides), indicating that Asn102 has an additional interaction
with the ligand other than this proposed H-bonding with the
C-terminal amide group. An alternative explanation, which
cannot be excluded by the present data, is that the Asn102 side
chain plays a role in configuring the agonist binding pocket,
such that mutation to Ala severely restricts access of agonists
with glycinamide, whereas it affects access less for agonists
with the less bulky ethylamide C terminus.
The importance of the C terminus of GnRH for binding was
demonstrated in early studies that showed that [des-
Gly10,Pro9-NH2]GnRH, which lacks the C-terminal glyci-
namide, had very low potency (11). The finding that the addi-
tion of an ethyl moiety to the C terminus of the latter peptide,
resulting in [Pro9-NEt]GnRH, restored high potency indicates
that the ethylamide peptides have gained an interaction, most
likely a hydrophobic interaction, which compensates for the
loss of the glycinamide. This explains why the ethylamide
analogs retained potencies for the wild-type GnRHR compara-
ble with their respective glycinamide analogs, despite the fact
that the ethylamide C terminus is incapable of hydrogen
bonding.
GnRH-OH, which has a carboxyl C terminus, was 325-fold
less potent than GnRH for the wild-type GnRHR and showed a
further 157-fold loss of potency for the [Ala102]GnRHR. The
latter finding indicates that the C-terminal carboxyl group
interacts with Asn102 in a manner similar to a C-terminal
amide group, consistent with a hydrogen bonding interaction.
The low potency of this analog for both receptors indicates that
there is some additional effect of the C-terminal carboxyl
group, which has adverse consequences for binding. Two pos-
sible interactions suggest themselves. First, the C-terminal
carboxyl could interact electrostatically with Arg8 of GnRH-
OH, which would be likely to have a marked effect on the
conformation of the peptide. Alternatively, the low potency of
GnRH-OH might be the result of the higher desolvation energy
of the carboxyl versus the amide group in water.
We have previously demonstrated that Glu301 in the mouse
GnRHR is a specific determinant of the selectivity of the
GnRHR for unconstrained GnRH analogs with Arg in position
8 of the peptide, suggesting an ionic interaction between Glu301
and Arg8 (26). Glu301 (equivalent to Asp302 in the human Gn-
RHR) is situated near the top of transmembrane helix 7. Based
on a survey of conserved residues in a large number of G-
protein-coupled receptor sequences, as well as mutagenesis
data, an arrangement of the transmembrane helices has been
proposed in which helix 7 is believed to lie adjacent to helix 2
(27, 28). This arrangement of the helices is supported by ex-
perimental evidence in the mouse GnRHR, in which an analy-
sis of the effects of reciprocal mutations of Asn87 (helix 2) and
Asp318 (helix 7) has suggested that these residues are in prox-
imity (29). Thus Asn102 and Asp302 are likely to be in close
proximity in the three-dimensional structure of the GnRHR
and may define a binding pocket accommodating Arg8 and the
C terminus of the ligand, as shown schematically in Fig. 3. This
site is also close in space to Lys121, located in the extracellular
third of transmembrane helix 3, which has been shown to be a
likely contact site for agonists but not antagonists (23).
In summary, we have shown that Asn102 of the GnRHR is a
critical determinant of potency for GnRH and analogs contain-
ing glycinamide at the C terminus. The results are consistent
with a direct interaction between the side chain of Asn102 and
the C terminus of the ligand. Alternatively, the effects of mu-
tating Asn102 may be mediated indirectly and reflect a role for
this residue in maintaining the conformation of the ligand
binding pocket.
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